Humacyte initiates Phase 2a trial of bioengineered vessel for coronary bypass surgery
HUMA•Humacyte began a first-in-human Phase 2a trial of its bioengineered coronary vessel, with enrollment open. The study will assess safety and efficacy in 10 adults, checking vessel patency at two months and following participants for up to three years.
1. Trial begins
Humacyte initiated the trial of its bioengineered coronary vessel for bypass surgery, with enrollment open. The study will assess safety and efficacy in 10 adults, check vessel patency at two months and follow participants through three years.
2. Preclinical findings
Animal studies showed the bypass vessels remained open and became populated with host cells. Trial design and preclinical results were presented at the American Heart Association Scientific Sessions in Chicago on Nov. 7-8, 2026.
